Abstract:The current study reported that combination of HER2 amplification and PD‐L1 expression in Chinese patients with gastric cancer could stratify the total populations into several subgroups with distinctive genomic and immune landscapes, which could be sensitive to different therapeutic regimens, indicating that both HER2 status and PD‐L1 expression level should be considered when making personalized treatment decisions for patients with advanced gastric cancer. Background Anti‐PD1/PD‐L1 antibody plus human epidermal growth factor receptor 2 (HER2) antibody and chemotherapy have become the new first‐line therapy for HER2 overexpression‐positive advanced gastric cancers (GC), suggesting that HER2 and PD‐L1 play a vital role in guiding systemic treatment for patients with GC. This study aimed to depict the genomic and immune landscapes of Chinese patients with GC and investigate their correlations with HER2 amplification and PD‐L1 expression. Patients and Methods Next‐generation targeted sequencing and PD‐L1 immunohistochemistry were performed on tumor samples from 735 patients with pathologically diagnosed GC. The genomic and immune landscapes and their correlations with HER2 amplification and PD‐L1 expression were analyzed. Results The most commonly mutated genes in Chinese GC were TP53 (64%), CDH1 (20%), ARID1A (18%), HMCN1 (15%), KMT2D (11%), and PIK3CA (11%). Seventy‐six (10%) patients were HER2 amplification, and 291 (40%) had positive PD‐L1 expression. Classifying the total population based on HER2 amplification and PD‐L1 expression level, 735 patients were divided into four subgroups: HER2+/PD‐L1+ (4.5%), HER2+/PD‐L1− (5.9%), HER2−/PD‐L1+ (35.1%), and HER2−/PD‐L1− (54.5%). The HER2+/PD‐L1− and HER2+/PD‐L1+ subgroups exhibited dramatically higher rate of TP53 mutations, CCNE1 and VEGF amplifications. The HER2+/PD‐L1− subgroup also had a markedly higher rate of MYC amplification and KRAS mutations. The HER2−/PD‐L1+ subgroup had significantly higher rate of PIK3CA mutations. HER2+/PD‐L1− subgroup had the highest TMB level and HER2−/PD‐L1+ subgroup had the highest proportion of patients with microsatellite instability‐high than other subgroups. Furthermore, we observed that different HER2 amplification levels had distinct impacts on the correlations between PD‐L1 expression and therapeutic genomic alterations, but no impact on the prognosis. Conclusion The combination of HER2 amplification and PD‐L1 expression in Chinese patients with GC could stratify the total populations into several subgroups with distinctive genomic and immune landscapes, which should be considered when making personalized treatment decisions.

Immunogenomic Classification of Gastric Cancer Based on the Tumor Microenvironments Expression of PD-L1 and CD8+T-cell Infiltration.

Clinicopathologic implications of immune classification by PD-L1 expression and CD8-positive tumor-infiltrating lymphocytes in stage II and III gastric cancer patients

Classification of Gastric Cancers Based on Immunogenomic Profiling.

Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients.

Integrated Assessment of PD-L1 Expression and Molecular Classification Facilitates Therapy Selection and Prognosis Prediction in Gastric Cancer

Characteristics of the Immune Cell Infiltration Landscape in Gastric Cancer to Assistant Immunotherapy

Identification and Validation of Tumour Microenvironment-Based Immune Molecular Subgroups for Gastric Cancer: Immunotherapeutic Implications

A Signature-Based Classification of Gastric Cancer That Stratifies Tumor Immunity and Predicts Responses to PD-1 Inhibitors

Cmar_a_206189 6397..6410

Analysis of PDL1 Expression and T Cells Infiltration in 1014 Gastric Cancer Patients.

Correlation Between Tumor Microenvironment and Immune Subtypes Based on CD8 T Cells Enhancing Personalized Therapy of Gastric Cancer

Integrative immunogenomic analysis of gastric cancer dictates novel immunological classification and the functional status of tumor-infiltrating cells

Immune Infiltration in Gastric Cancer Microenvironment and Its Clinical Significance

Immune Cell Landscape in Gastric Cancer

PD-L1 expression is a prognostic factor in subgroups of gastric cancer patients stratified according to their levels of CD8 and FOXP3 immune markers.

Profiles of PD-1, PD-L1, PD-L2 in Gastric Cancer and Their Relation with Mutation, Immune Infiltration, and Survival

The genomic and immune landscapes of gastric cancer and their correlations with HER2 amplification and PD‐L1 expression

Tumor Immunophenotyping‐Derived Signature Identifies Prognosis and Neoadjuvant Immunotherapeutic Responsiveness in Gastric Cancer

Immune landscape of advanced gastric cancer tumor microenvironment identifies immunotherapeutic relevant gene signature

Characterization of Immune-Related Molecular Subtypes and a Prognostic Signature Correlating with the Response to Immunotherapy in Patients with Gastric Cancer

Predicting response to immunotherapy in gastric cancer via multi-dimensional analyses of the tumour immune microenvironment